Paper Details

  1. Home
  2. Paper Details

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.

Author: AbrahamPrema, BankertJoy M, BrownDavid, ChongSandy, CiullaThomas, DanielPaul E, HeierJeffrey S, KimIvana K

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ranibizumab was effective and safe for treating choroidal neovascularization due to causes other than age-related macular degeneration, with no significant difference in efficacy between monthly injections and pro re nata dosing.
Paper Details　
Original Abstract of the Article :
PURPOSE: To investigate the safety and efficacy of ranibizumab for the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD). DESIGN: Multicenter, randomized, 12-month clinical trial. PARTICIPANTS: Thirty patients with CNV due to caus...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ophtha.2010.04.016

データ提供：米国国立医学図書館（NLM）

Ranibizumab for Choroidal Neovascularization Secondary to Causes Other than Age-Related Macular Degeneration

Choroidal neovascularization (CNV), like a pesky sandstorm in our eyes, can disrupt our vision. While ranibizumab is an effective treatment for CNV in age-related macular degeneration (AMD), its effectiveness for other causes of CNV is less clear. This study, like a pioneering desert explorer venturing into uncharted territory, investigates the safety and efficacy of ranibizumab for treating CNV secondary to causes other than AMD.

A Promising Treatment Option

The researchers conducted a phase I clinical trial to assess the safety and efficacy of ranibizumab in patients with CNV due to causes other than AMD. They found that ranibizumab was well-tolerated and showed promising results in improving visual acuity and reducing central retinal thickness.

Improving Vision

This study provides encouraging evidence that ranibizumab may be a valuable treatment option for CNV caused by factors other than AMD. Further research is needed to confirm these findings and to optimize treatment strategies.

Dr.Camel's Conclusion

Just as a camel can navigate through a maze of sand dunes, healthcare professionals must navigate the complex landscape of treatment options for CNV. This study offers hope for patients with CNV due to causes other than AMD, suggesting that ranibizumab may be a key to restoring vision.

Date :
  1. Date Completed 2011-01-28
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

20678799

DOI: Digital Object Identifier

10.1016/j.ophtha.2010.04.016

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.